तुलना करने के लिए मीट्रिक्स | GENIG | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधGENIGपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −1.9x | −1.0x | −0.5x | |
PEG अनुपात | −0.03 | −0.02 | 0.00 | |
क़ीमत/बुक | 3.5x | 0.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 3.2x | 0.6x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 61.3% | 48.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | 24.6% | 5.6% | अनलॉक करें |
GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient’s health based on their genes in the United Kingdom and internationally. Its predictive technology offers patients and physicians with preventative care and treatment strategies. The company’s invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a genetic test to help user to adopt cardiovascular prevention assesment; Lipid inCode, a genetic diagnostic test for familial hypercholesterolemia FH; SUDD inCode, genetic diagnostic test for familial heart diseases; Thrombo inCode, a genetic test for diagnosis of hereditary thrombophilia and the risk of thrombosis. In addition, the company offers Thrombo inCode Reproductive Health, is a genetic test that evaluates the impact of hereditary thrombophilia in patients with repeated miscarriages; and ROCA Test, a blood test that determines the risk of a woman having ovarian cancer. Further, it engages in the medical and scientific research activities. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.